T. Rowe Price Associates’s Takeda Pharmaceutical TAK Stock Holding History

T. Rowe Price Associates’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.52M	Sell	94,848 -45,345	-32%	-$750K	﹤0.01%	2134
2026 Q1	$2.6M	Buy	+140,193	New	+$2.46M	﹤0.01%	1714
2021 Q4	–	Sell	-5,518,932	Closed	-$90.4M	–	3039
2021 Q3	$90.4M	Buy	5,518,932 +132,629	+2%	+$2.23M	0.01%	800
2021 Q2	$90.7M	Sell	5,386,303 -50,595	-0.9%	-$861K	0.01%	814
2021 Q1	$99.3M	Buy	5,436,898 +74,254	+1%	+$1.34M	0.01%	781
2020 Q4	$97.6M	Sell	5,362,644 -20,922	-0.4%	-$367K	0.01%	731
2020 Q3	$96M	Sell	5,383,566 -111,770	-2%	-$2.04M	0.01%	667
2020 Q2	$98.5M	Sell	5,495,336 -72,130	-1%	-$1.29M	0.01%	643
2020 Q1	$84.5M	Buy	5,567,466 +1,458,068	+35%	+$26.4M	0.01%	619
2019 Q4	$81.1M	Sell	4,109,398 -46,969	-1%	-$899K	0.01%	736
2019 Q3	$71.5M	Sell	4,156,367 -19,531	-0.5%	-$338K	0.01%	734
2019 Q2	$73.9M	Sell	4,175,898 -1,780,699	-30%	-$32.4M	0.01%	737
2019 Q1	$121M	Buy	+5,956,597	New	+$120M	0.02%	587

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

T. Rowe Price Associates's TAK Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Takeda Pharmaceutical (TAK) stake by 32% in Q2 2026, selling an estimated $750K and leaving 94,848 shares worth $1.52M. The position accounts for ﹤0.01% of the portfolio, ranked #2134.

T. Rowe Price Associates first reported a position in TAK in Q1 2019 and has held it in 13 quarters since. The position peaked at $121M in Q1 2019. 375 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

T. Rowe Price Associates held 94,848 shares of Takeda Pharmaceutical worth $1.52M as of Q2 2026.
T. Rowe Price Associates sold 45,345 Takeda Pharmaceutical shares in Q2 2026, an estimated $750K.
Takeda Pharmaceutical made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2134 holding.
T. Rowe Price Associates first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 13 quarters since.
T. Rowe Price Associates's Takeda Pharmaceutical position peaked at $121M in Q1 2019.
375 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.